Identifying DEK as a Tumor Antigen in Neuroblastoma
Author Information
Author(s): Zheng Jin, Kohler M Eric, Chen Qingrong, Weber James, Khan Javed, Johnson Bryon D, Orentas Rimas J
Primary Institution: Medical College of Wisconsin and the National Cancer Institute
Hypothesis
The use of serum from vaccinated mice in the context of Treg inhibition can identify novel tumor antigens.
Conclusion
The study successfully identified DEK as a tumor-associated antigen that can elicit a T cell response, suggesting its potential as a target for immunotherapy.
Supporting Evidence
- DEK was identified 34 times in the screening process, indicating its prominence as a target.
- Serum from vaccinated mice showed a strong immune response against DEK.
- Blocking Treg function enhanced the immune response to the tumor vaccine.
Takeaway
Researchers found a way to identify a protein called DEK that can help the immune system fight a type of cancer called neuroblastoma by using blood from vaccinated mice.
Methodology
Mice were vaccinated with a modified neuroblastoma cell line and treated with an antibody to block Treg function, followed by serum analysis to identify tumor antigens.
Limitations
The study primarily used a murine model, which may not fully translate to human responses.
Participant Demographics
A/J mice, 6–8 weeks of age.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website